Effect of ibuprofen on bilirubin-albumin binding in vitro at concentrations observed during treatment of patent ductus arteriosus

Early Human Development

Volumn 86, Issue 5, 2010, Pages 315-317

  Diot, C ^a   Kibleur, Y ^c   Desfrere, L ^b  

^a SGS Cephac Europe   (France)

^b HÔPITAL LOUIS MOURIER   (France)

^c Orphan Europe   (France)

Author keywords

Ibuprofen; Kernicterus; Neonate; Patent ductus arteriosus; Preterm infants; Unbound bilirubin

Indexed keywords

ALBUMIN; BILIRUBIN; IBUPROFEN; PEROXIDASE; ALBUMINOID; ANALGESIC AGENT; PROTEIN BINDING;

ANALYTIC METHOD; ARTICLE; BILIRUBIN BLOOD LEVEL; BINDING COMPETITION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BINDING SITE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG PROTEIN BINDING; HUMAN; IN VITRO STUDY; INFANT; LOADING DRUG DOSE; PATENT DUCTUS ARTERIOSUS; PREMATURITY; RECOMMENDED DRUG DOSE; BINDING SITE; DOSE RESPONSE; DRUG EFFECTS; DUCTUS ARTERIOSUS, PATENT; EVALUATION STUDY; METABOLISM; NEWBORN; NEWBORN SCREENING; OSMOLARITY; STANDARDS;

ALBUMINS; ANALGESICS, NON-NARCOTIC; BILIRUBIN; BINDING SITES; DOSE-RESPONSE RELATIONSHIP, DRUG; DUCTUS ARTERIOSUS, PATENT; HUMANS; IBUPROFEN; IN VITRO TECHNIQUES; INFANT, NEWBORN; NEONATAL SCREENING; OSMOLAR CONCENTRATION; PROTEIN BINDING;

EID: 77954030963     PISSN: 03783782     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.earlhumdev.2010.04.006     Document Type: Article

References (23)

1. Mosca F., Bray M., Lattanzio M., Fumagalli M., Tosetto C. Comparative evaluation of the effects of indomethacin and ibuprofen on cerebral perfusion and oxygenation in preterm infants with patent ductus arteriosus. J Pediatr 1997, 131(4):549-554.
2. Pezzati M., Vangi V., Biagiotti R., Bertini G., Cianciulli D., Rubaltelli F.F. Effects of indomethacin and ibuprofen on mesenteric and renal blood flow in preterm infants with patent ductus arteriosus. J Pediatr 1999, 135(6):733-738.
3. Cooper-Peel C., Brodersen R., Robertson A. Does ibuprofen affect bilirubin-albumin binding in newborn infant serum?. Pharmacol Toxicol 1996, 79(6):297-299.
4. Honore B., Brodersen R. Albumin binding of anti-inflammatory drugs. Utility of a site-oriented versus a stoichiometric analysis. Mol Pharmacol 1984, 25(1):137-150.
5. Ahlfors C.E. Effect of ibuprofen on bilirubin-albumin binding. J Pediatr 2004, 144(3):386-388.
6. Aranda J.V., Clyman R., Cox B., Van Overmeire B., Wozniak P., Sosenko I., et al. A randomized, double-blind, placebo-controlled trial on intravenous ibuprofen l-lysine for the early closure of nonsymptomatic patent ductus arteriosus within 72hours of birth in extremely low-birth-weight infants. Am J Perinatol 2009, 26(3):235-245.
7. Desfrere L., Zohar S., Morville P., Brunhes A., Chevret S., Pons G., et al. Dose-finding study of ibuprofen in patent ductus arteriosus using the continual reassessment method. J Clin Pharm Ther 2005, 30(2):121-132.
8. Gregoire N., Gualano V., Geneteau A., Millerioux L., Brault M., Mignot A., et al. Population pharmacokinetics of ibuprofen enantiomers in very premature neonates. J Clin Pharmacol 2004, 44(10):1114-1124.
9. Van Overmeire B., Touw D., Schepens P.J., Kearns G.L., van den Anker J.N. Ibuprofen pharmacokinetics in preterm infants with patent ductus arteriosus. Clin Pharmacol Ther 2001, 70(4):336-343.
10. Gournay V., Roze J.C., Kuster A., Daoud P., Cambonie G., Hascoet J.M., et al. Prophylactic ibuprofen versus placebo in very premature infants: a randomised, double-blind, placebo-controlled trial. Lancet 2004, 364(9449):1939-1944.
11. Desfrere L., Mourdie J., Barbier A., Moriette G. Effect of ibuprofen on unbound bilirubin levels in preterm newborns, [Absract]. PAS Annual Meeting 2007 2007, 8447.11.
12. Ahlfors C.E. Measurement of unbound bilirubin by the peroxidase test using zone fluidics. Chim Clin Acta 2006, 365:78-85.
13. Ahlfors C.E., Vreman H., Wrong R., Bender G., Oh W., Morris B., et al. Effect of sample dilution, peroxidase concentration, and chloride ion on the measurement of unbound bilirubin in premature newborns. Clin Biochem 2007, 40(3-4):261-267.
14. Ahlfors C.E. Unbound bilirubin associated with kernicterus: a historical approach. J Pediatr 2000, 137(4):540-544.
15. Brodersen R. Competitive binding of bilirubin and drugs to human serum albumin studied by enzymatic oxidation. J Clin Invest 1974, 54(6):1353-1364.
16. Odell G., Storey G., Rosenberg L. Studies in kernicterus.3. The saturation of serum proteins with bilirubin during neonatal life and its relationship to brain damage at five years. J Pediatr 1970, 76(1):12-21.
17. Ambat M.T., Ostrea E.M., Aranda J.V. Effect of ibuprofen l-lysinate on bilirubin binding to albumin as measured by saturation index and horseradish peroxidase assays. J Perinatol 2008, 28(4):287-290.
18. Van Overmeire B., Vanhagendoren S., Schepens P.J., Ahlfors C.E. Abstract. Pediatr Res 2004, 2687.
19. Rheinlaender C., Helfenstein D., Walch E., Berns M., Obladen M., Koehne P. Total serum bilirubin levels during cyclooxygenase inhibitor treatment for patent ductus arteriosus in preterm infants. Acta Paediatr 2009, 98(1):36-42.
20. Zecca E., Romagnoli C., De Carolis M., Costa S., Marra R., De Luca D. Does ibuprofen increase neonatal hyperbilirubinemia?. Pediatrics 2009, 124(2):480-484.
21. Aranda J.V., Varvarigou A., Beharry K., Bansal R., Bardin C., Modanlou H., et al. Pharmacokinetics and protein binding of intravenous ibuprofen in the premature newborn infant. Acta Paediatr 1997, 86(3):289-293.
22. Ahlfors C.E. Benzyl alcohol, kernicterus, and unbound bilirubin. J Pediatr 2001, 139(2):317-319.
23. Hirt D., Van Overmeire B., Treluyer J.M., Langhendries J.P., Marguglio A., Eisinger M.J., et al. An optimized ibuprofen dosing scheme for preterm neonates with patent ductus arteriosus, based on a population pharmacokinetic and pharmacodynamic study. Br J Clin Pharmacol 2008, 65(5):629-636.